Thalys Medical Technology Group Corporation (SHA:603716)
China
· Delayed Price · Currency is CNY 21.06
+0.15 (0.72%)
Apr 29, 2026, 3:00 PM CST
SHA:603716 Revenue
Thalys Medical Technology Group had revenue of 181.79M CNY in the quarter ending March 31, 2026, a decrease of -36.75%. This brings the company's revenue in the last twelve months to 971.32M, down -39.78% year-over-year. In the year 2025, Thalys Medical Technology Group had annual revenue of 1.08B, down -40.52%.
Revenue (ttm)
971.32M
Revenue Growth
-39.78%
P/S Ratio
4.61
Revenue / Employee
779.55K
Employees
1,246
Market Cap
4.48B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.08B | -733.73M | -40.52% |
| Dec 31, 2024 | 1.81B | -195.45M | -9.74% |
| Dec 31, 2023 | 2.01B | -302.50M | -13.10% |
| Dec 31, 2022 | 2.31B | -290.92M | -11.19% |
| Dec 31, 2021 | 2.60B | 474.08M | 22.30% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| SMO ClinPlus CO.,LTD. | 819.09M |
| Guangdong Hybribio Biotech | 691.16M |
| Shanghai Labway Clinical Laboratory | 1.52B |
| Medicalsystem Biotechnology | 1.54B |
| Berry Genomics Co.,Ltd | 941.16M |
| Cowealth Medical China | 656.38M |
| Maccura Biotechnology Co.Ltd | 2.21B |
| Chemclin Diagnostics | 353.32M |